Novartis inks $5.7B pact with Monte Rosa to develop immunology treatments

Novartis agreed to develop immune-mediated disease treatments with Monte Rosa Therapeutics in a deal worth up to $5.7 billion.

Why it matters: It's the second transaction the two parties have inked in the last year.